Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CsA, comparably to pharmacological inhibitors of PI3K/Akt signaling (LY294002, A443654), reduced motility of glioblastoma cells, diminished MMP-2 gelatinolytic activity and MMP-2 and MT1-MMP expression.
|
21276823 |
2011 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Curcumin and Solid Lipid Curcumin Particles Induce Autophagy, but Inhibit Mitophagy and the PI3K-Akt/mTOR Pathway in Cultured Glioblastoma Cells.
|
30669284 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
|
12545160 |
2003 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) mutations (EGFRvIII) and phosphoinositide 3-kinase (PI3K) hyperactivation are common in GBM, promoting tumor growth and survival, including through sterol regulatory element-binding protein 1 (SREBP-1)-dependent lipogenesis.
|
22059152 |
2011 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, combining gefitinib with inhibitors of the PI3K/AKT pathway show enhanced cytotoxicity in glioblastoma derived cell lines.
|
18566746 |
2008 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
|
27448972 |
2016 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, photofrin based PDT followed by miR-99a transfection dramatically increased miR-99a expression and also increased apoptosis in glioblastoma cell cultures and drastically reduced tumor growth in athymic nude mice, due to down regulation of fibroblast growth factor receptor 3 (FGFR3) and PI3K/Akt signaling mechanisms leading to inhibition of cell proliferation and induction of molecular mechanisms of apoptosis.
|
23409016 |
2013 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GDC-0084 is a brain penetrant, dual PI3K/mTOR inhibitor that has shown promising activity in a preclinical model of glioblastoma.
|
30796030 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene expression and clinical relevance of PI3K genes in GBM patients were analyzed using online databases.
|
29016844 |
2018 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic analyses demonstrated that EGFR-Ras and PI3K induce fly glial neoplasia through activation of a combinatorial genetic network composed, in part, of other genetic pathways also commonly mutated in human glioblastomas.
|
21538561 |
2011 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic lesions in glioblastoma (GB) include constitutive activation of PI3K and EGFR pathways to drive cellular proliferation and tumor malignancy.
|
30506943 |
2019 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genomic analyses reveal that signature genetic lesions in GBM and LGG include copy gain and amplification of chromosome 7, amplification, mutation, and overexpression of receptor tyrosine kinases (RTK) such as EGFR, and activating mutations in components of the PI3K pathway.
|
30530503 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we identified that WEE1 is activated after transient exposure to PI3K inhibition and confers resistance to PI3K inhibition in GBM.
|
29016926 |
2018 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that overexpression of NEU3 in glioblastoma U87MG cells activates PI3K/Akt signaling pathway resulting in an increased radioresistance capacity and in an improved efficiency of double strand DNA-repair mechanisms after irradiation.
|
30466783 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed the effect of AG1433 (a PDGFR inhibitor), SU1498 (a VEGFR inhibitor) and BEZ235 (a PI3K/Akt/mTOR signaling pathways inhibitor) on glioblastoma cells in vitro.
|
26339347 |
2015 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we report on the analysis of 17 genes related to the Pi3k/Akt signalling pathway for genetic alteration and aberrant expression in a series of 103 glioblastomas.
|
14655756 |
2003 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, due to the development of resistance mechanisms, kinase inhibition studies targeting the PI3K-AKT pathway for relapsing glioblastoma have mostly failed thus far.
|
25256166 |
2014 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors.
|
22015553 |
2012 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we demonstrate that the extracellular signal-regulated kinase (ERK)1/2 pathway is only partially implicated in the modulation of CXCL12-induced glioblastoma cell movement, whereas the phosphoinositol-3 kinase (PI3K) pathway is not involved.
|
20392929 |
2010 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we detected decreased nuclear localization of Nrf2 following combined treatment with ERK and PI3K inhibitors in three human glioblastoma cell lines and selected the cell line (U251) most sensitive to the inhibitors for further study.
|
23708697 |
2013 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, PI3K inhibitors are promising agents in the treatment of glioblastomas, especially when used in combination with ionizing radiation.
|
18413797 |
2008 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, DPT effectively inhibited the expression of PI3K and downregulated PI3K/Akt‑mediated signaling pathways to prevent glioblastoma progression.
|
30816477 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the combined inhibition of PI3K/Akt/mTOR and SHH pathways was superior to single pathway inhibition in suppressing glioblastoma growth by targeting GICs.
|
30251117 |
2019 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the current study demonstrated for the first time that inhibition of RWDD3 expression inhibited glioblastoma progression, at least partly, via suppressing the PI3K/AKT signaling activity, and thus RWDD3 may be a novel potential therapeutic target for glioblastoma.
|
29977365 |
2018 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |